Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Eli Lilly has delivered a jaw-dropping 635% stock price increase from 2020 to 2024, driven by high hopes and heavyweight drug ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Doctors have explained what the 'golden dosing' trend does to your body as Ozempic and Mounjaro rise in popularity for weight ...

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...